2023 will be a ‘transition year’ for COVID-19 vaccines, says Pfizer
The model for COVID-19 vaccines will undoubtedly change next year: but what this will look like in terms of key metrics such as number of doses and revenues remains in question.
Archives for November 4, 2022
Lonza: N-1 perfusion capability enables increased process titers
The biopharma sector has seen recent advancements in process intensification, especially in relation to upstream processing, with the technology employed aimed at increasing drug output. One of the quickest and simplest ways to achieve process...
AstraZeneca and Sanofi secure EU approval for antibody to prevent RSV in infants
AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the EU the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.